|

Docetaxel Injection Clinical Trials

9 actively recruiting trials

Also known as: Docetaxel

Pipeline

Phase 2: 2Phase 3: 4Phase 1/2: 2Phase 2/3: 1

Top Sponsors

Nanjing Leads Biolabs Co.,Ltd2
Jiangsu HengRui Medicine Co., Ltd.2
Shanghai Miracogen Inc.1
Shanghai JMT-Bio Inc.1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd1

Indications

Cancer9
Breast Cancer3
Advanced or Metastatic Urothelium Cancer1
Advanced Solid Tumour1
Early-stage or Locally Advanced HER2-positive Breast Cancer1

Other9 trials

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

Phase 2

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

Phase 1/2

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Phase 3

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Phase 3

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Phase 3

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Phase 2

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Phase 3

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.